Wall Street analyst estimates for Pasithea Therapeutics Corp. (KTTA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.21 | ||
| 2026-08-14 | $-0.16 | $-0.16 | +0.0% |
| 2026-05-15 | $-0.12 | $-0.45 | +73.3% |
| 2026-03-30 | $-0.89 | $-0.18 | -394.4% |
| 2025-11-13 | $-0.41 | $-0.18 | -127.8% |
| 2025-08-14 | $-0.66 | ||
| 2025-05-15 | $-1.61 | ||
| 2025-03-24 | $-2.41 |
Valuation Ratios
| Price / Book | 0.07 |
| EV / EBITDA | 1958.83 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | $15062 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | $17275 | $5094 | 0 | 0 | 0 |
| Gross Profit | 0 | -$2213 | -$5094 | 0 | 0 | 0 |
| Research & Development | 0 | 0 | $2.7M | $8.1M | $7.2M | $8.0M |
| Selling, General & Admin | 0 | $4.5M | $9.9M | $7.9M | $7.1M | $12.9M |
| Operating Expenses | $61476 | $4.5M | $12.6M | $16.0M | $14.2M | $20.9M |
| Operating Income | -$61476 | -$4.5M | -$12.6M | -$16.0M | -$14.2M | -$20.9M |
| EBITDA | 0 | -$2.2M | -$11.7M | -$15.3M | -$13.6M | -$20.2M |
| Interest Expense | 0 | $508 | $102 | 0 | 0 | 0 |
| Pre-tax Income | -$61476 | -$2.2M | -$11.7M | -$15.5M | -$13.9M | -$20.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$61476 | -$2.2M | -$13.9M | -$16.0M | -$13.9M | -$20.4M |
| EPS | $-0.06 | $-4.20 | $-10.34 | $-13.01 | $-12.69 | $-2.91 |
| EPS (Diluted) | $-0.06 | $-4.20 | $-10.34 | $-13.01 | $-12.69 | $-2.91 |
| Shares Outstanding (Diluted) | $688918 | $520233 | $1.3M | $1.2M | $1.1M | $7.0M |
Price
| Price | $0.49 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AIM · CYCN · IBO · KALA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of KTTA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks